公开(公告)号：WO1996040763A2

公开(公告)日：1996-12-19

申请号：PCT/US1996009655

申请日：1996-06-07

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BRIDON, Dominique, P. ,  SZE, Isaac, S.-Y. ,  DAGHFAL, David, J. ,  JAFFE, Keeve, D. ,  COLPITTS, Tracey, L.

IPC: C07K14/16

CPC classification number: C07K14/005 ,  C12N2740/16122 ,  Y10S435/974 ,  Y10S435/975 ,  Y10S530/806 ,  Y10S530/812 ,  Y10S530/826

Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp 160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.

Abstract translation: HIV-1肽在HIV-1 gp 160氨基酸序列的位置593和611之间具有至少一个点突变。 点突变处于位置604或610，或两个位置。 提供了利用这些肽的免疫测定，以及含有这些肽的诊断测试试剂盒。

公开(公告)号：WO1994020636A1

公开(公告)日：1994-09-15

申请号：PCT/US1994002539

申请日：1994-03-09

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BRATE, Elaine, M. ,  BRENNAN, Catherine, A. ,  BRIDON, Dominique, P. ,  JAFFE, Keeve, D. ,  KRAFFT, Grant, A. ,  MANDECKI, Wlodzimierz ,  MARCH, Steven, C. ,  RUSSELL, John, C. ,  YUE, Vincent, T.

IPC: C12Q01/00

CPC classification number: C07K14/59 ,  C07K2319/40 ,  C12N9/16 ,  C12Q1/42

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

Abstract translation: 本发明涉及基因工程改造的酶，其配体缀合物，其制备及其在定性或定量测定中的用途。 诸如AP-表位的杂交酶在起始AP酶的活性位点附近插入外源氨基酸部分（表位）。 外来氨基酸部分与分析物结合，并且作为该结合的结果，修饰了杂合酶AP-表位的酶活性。 酶活性的变化取决于分析物的存在或数量。 在另一个实施方案中，杂交酶由在AP的活性位点附近引入的半胱氨酸组成以产生杂交酶。 杂交酶上的半胱氨酸用作配体如茶碱，铁蛋白，甲状腺素或地高辛的缀合点，以形成杂交酶 - 配体缀合物。 配体与分析物结合抗体，分析物或结合分子，作为该结合的结果，修饰或调节杂交酶 - 配体结合物的酶活性。

公开(公告)号：EP0832113B1

公开(公告)日：2004-05-19

申请号：EP96921412.1

申请日：1996-06-07

Applicant: Abbott Laboratories

Inventor： BRIDON, Dominique, P. ,  SZE, Isaac, S.-Y. ,  DAGHFAL, David, J. ,  JAFFE, Keeve, D. ,  COLPITTS, Tracey, L.

IPC: C07K14/16 ,  G01N33/68

CPC classification number: C07K14/005 ,  C12N2740/16122 ,  Y10S435/974 ,  Y10S435/975 ,  Y10S530/806 ,  Y10S530/812 ,  Y10S530/826

公开(公告)号：EP0832113A2

公开(公告)日：1998-04-01

申请号：EP96921412.0

申请日：1996-06-07

Applicant: Abbott Laboratories

Inventor： BRIDON, Dominique, P. ,  SZE, Isaac, S.-Y. ,  DAGHFAL, David, J. ,  JAFFE, Keeve, D. ,  COLPITTS, Tracey, L.

IPC: G01N33 ,  C07K14

CPC classification number: C07K14/005 ,  C12N2740/16122 ,  Y10S435/974 ,  Y10S435/975 ,  Y10S530/806 ,  Y10S530/812 ,  Y10S530/826

Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp 160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.

公开(公告)号：EP0688364A1

公开(公告)日：1995-12-27

申请号：EP94913281.0

申请日：1994-03-09

Applicant: ABBOTT LABORATORIES

Inventor： BRATE, Elaine, M. ,  BRENNAN, Catherine, A. ,  BRIDON, Dominique, P. ,  JAFFE, Keeve, D. ,  KRAFFT, Grant, A. ,  MANDECKI, Wlodzimierz ,  MARCH, Steven, C. ,  RUSSELL, John, C. ,  YUE, Vincent, T.

IPC: G01N33 ,  C07K14 ,  C12N9 ,  C12N15 ,  C12Q1 ,  C12R1

CPC classification number: C07K14/59 ,  C07K2319/40 ,  C12N9/16 ,  C12Q1/42

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.